arrow
S

Simon Travis

University of Oxford
H指数:97
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A therapeutic atlas of monogenic inflammatory bowel disease

单基因炎症性肠病的治疗图谱

2026-09-120
OAAI
Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn’s disease

克罗恩病中基质细胞状态的表观遗传调控是病理组织微环境的基石

2026-08-120
OA
Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial

克罗恩病中的肠道急迫感:美利曲珠单抗在随机对照III期试验中的效果

2025-07-140
OAAI
Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn’s Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey

溃疡性结肠炎和克罗恩病中肠道急迫性的广泛影响:来自“炎症性肠病体验需求与特征沟通”(CONFIDE)调查的美国、欧洲和日本患者及医疗专业人员观点

2025-07-110
OA
Magnetic resonance enterography to predict subsequent disabling Crohn's disease in newly diagnosed patients (METRIC-EF)-multivariable prediction model, multicentre diagnostic inception cohort

磁共振小肠造影预测新诊断患者后续致残性克罗恩病(METRIC-EF)-多变量预测模型,多中心诊断起始队列

2025-05-140
OA
TRANSLATING 5-HT4R AGONISM INTO MENTAL ILLNESS: POTENTIAL CLINICAL APPLICATIONS FOR MOOD DISORDER AND COGNITIVE IMPAIRMENT

将5-HT4R激动作用应用于精神疾病:针对心境障碍和认知障碍的潜在临床应用

2025-02-120
OA
Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
2025-01-221
PRE
Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
2025-01-220
PRE
Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
2025-01-220
PRE
Burden and Impact of Abdominal Pain in Moderate to Severe Crohn's Disease and Ulcerative Colitis: Results from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey

中重度克罗恩病和溃疡性结肠炎患者腹部疼痛的负担及影响:来自沟通炎症性肠病需求与特征体验(CONFIDE)调查的结果

2024-12-010
OA